These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 15677776

  • 1. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
    Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A, INITIATE Study Group.
    Diabetes Care; 2005 Feb; 28(2):260-5. PubMed ID: 15677776
    [Abstract] [Full Text] [Related]

  • 2. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [Abstract] [Full Text] [Related]

  • 3. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
    Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):527-32. PubMed ID: 17115351
    [Abstract] [Full Text] [Related]

  • 4. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P.
    Endocr Pract; 2011 Oct; 17(1):41-50. PubMed ID: 20713345
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [Abstract] [Full Text] [Related]

  • 7. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.
    Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
    [Abstract] [Full Text] [Related]

  • 8. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU, Plewe G, Busch K.
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs.
    Kalra S, Plata-Que T, Kumar D, Mumtaz M, Søndergaard F, Kozlovski P, Bebakar WM.
    Diabetes Res Clin Pract; 2010 Jun; 88(3):282-8. PubMed ID: 20363044
    [Abstract] [Full Text] [Related]

  • 11. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
    Kvapil M, Swatko A, Hilberg C, Shestakova M.
    Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
    [Abstract] [Full Text] [Related]

  • 12. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
    Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators.
    Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
    [Abstract] [Full Text] [Related]

  • 13. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 14. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
    Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH, Lispro Mixture-Glargine Study Group.
    Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
    [Abstract] [Full Text] [Related]

  • 15. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 16. Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine.
    Moses AC, Raskin P, Khutoryansky N.
    Diabet Med; 2008 Feb; 25(2):200-5. PubMed ID: 18290862
    [Abstract] [Full Text] [Related]

  • 17. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

  • 18. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P, Wojciechowski P, Siejka S, Małecki P, Hak L, Malecki MT.
    Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
    [Abstract] [Full Text] [Related]

  • 19. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [Abstract] [Full Text] [Related]

  • 20. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.
    Ann Intern Med; 2008 Oct 21; 149(8):531-9. PubMed ID: 18936501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.